Memantine Hydrochloride Tablet
Product Images NDC 0591-3870

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0591-3870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets 01

Chemical structure diagram of memantine hydrochloride, showing the molecular framework with labeled amine (NH2) and hydrochloride (HCl) groups, as well as methyl (CH3) substituents on the bicyclo[3.3.1]nonane skeleton.*

FDA Label Image

Memantine Hydrochloride Tablets 02

A line graph depicting the mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing memantine hydrochloride to placebo. The x-axis shows weeks of treatment (0, 4, 12, 28). The y-axis shows mean change from baseline with error bars. The graph illustrates clinical improvement above zero and clinical decline below zero, with memantine HCl showing less decline than placebo over time.*

FDA Label Image

Memantine Hydrochloride Tablets 03

A cumulative percentage curve graph depicting patients completing 28 weeks of double-blind treatment, comparing placebo and memantine hydrochloride groups. The x-axis shows ADCS-ADL change from baseline, with values ranging approximately from 10 to -25. The y-axis represents the cumulative percentage of patients, ranging from 0% to 100%. Two curves are shown: one for placebo (square markers) and one for memantine HCl (circle markers). The graph illustrates relative differences in patient responses based on ADCS-ADL scores.*

FDA Label Image

Memantine Hydrochloride Tablets 04

A line graph illustrating the mean change from baseline in SIB (Severe Impairment Battery) score over 28 weeks of treatment for memantine hydrochloride compared to placebo. The y-axis shows mean change from baseline in SIB score, with clinical improvement and decline indicated, and the x-axis shows weeks of treatment. Error bars represent SEM. Two lines plot scores for placebo (showing decline) and memantine HCl (showing stability).*

FDA Label Image

Memantine Hydrochloride Tablets 05

A cumulative percentage graph comparing patients treated with memantine hydrochloride versus placebo over 28 weeks, showing changes from baseline in SIB (Severe Impairment Battery) scores. The x-axis represents SIB change from baseline, ranging approximately from 10 to -30, and the y-axis represents the cumulative percentage of patients, ranging from 0 to 100%. The graph includes two lines: one for memantine HCl and one for placebo, illustrating patient response differences in the clinical study.*

FDA Label Image

Memantine Hydrochloride Tablets 06

Line graph depicting time course of change from baseline in ADCS-ADL score over 24 weeks of treatment. The graph compares two groups: placebo/donepezil and memantine hydrochloride/donepezil, showing mean changes with error bars across multiple time points, indicating clinical improvement or decline.*

FDA Label Image

Memantine Hydrochloride Tablets 07

A cumulative percentage chart showing the percentage of patients completing 24 weeks of double-blind treatment versus changes from baseline in ADCS-ADL scores. The graph compares two groups: placebo/donepezil and memantine HCl/donepezil, with cumulative percentage on the y-axis and ADCS-ADL change from baseline on the x-axis.*

FDA Label Image

Memantine Hydrochloride Tablets 08

A line graph showing the mean change from baseline in SIB score over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil. The vertical axis represents the mean change in SIB score with error bars, ranging from clinical decline to clinical improvement. The horizontal axis shows weeks of treatment from 0 to 24. The Memantine HCl/Donepezil group shows an increase peaking around week 12, then a gradual decline, while the Placebo/Donepezil group remains near baseline or declines over time.*

FDA Label Image

Memantine Hydrochloride Tablets 09

A cumulative percentage chart showing patient response over a 24-week double-blind treatment period. The x-axis represents SIB (Severe Impairment Battery) change from baseline, ranging from +20 to -30, and the y-axis shows the cumulative percentage of patients, from 0% to 100%. Two groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil, with Memantine HCl/Donepezil showing a greater negative change in SIB scores over time.*

FDA Label Image

Memantine Hydrochloride Tablets 0a

Memantine HCl Tablets 5 mg oral tablets packaging label by Actavis Pharma, Inc. The label indicates a quantity of 60 tablets, prescription use only, with instructions on storage and dosage. It includes the NDC number 0591-3870-60 and licensing information from Merz Pharma GmbH & Co. KGaA, made in Ireland.*

FDA Label Image

Memantine Hydrochloride Tablets 0b

Packaging label for Memantine HCl Tablets 5 mg by Actavis Pharma, Inc. The carton contains 10 blister cards with a total of 100 tablets. The label includes the NDC 0591-3870-44 and states the product is for Rx only. Storage instructions and distributor details are also present.*

FDA Label Image

Memantine Hydrochloride Tablets 0c

Label for Memantine HCl Tablets, 10 mg strength, oral tablet form by Actavis Pharma, Inc. The label states 60 tablets per bottle with prescription only use. It includes storage instructions, ingredient information, manufacturer licensing details, and barcodes.*

FDA Label Image

Memantine Hydrochloride Tablets 0d

Packaging label for Memantine HCl Tablets 10 mg by Actavis Pharma, Inc. The label indicates the product contains 10 mg memantine hydrochloride per tablet and is supplied as 10 x 10 blister cards (100 tablets total). The NDC number 0591-3875-44 and Rx Only designation are visible. Storage and licensing information are also included.*

FDA Label Image

Memantine Hydrochloride Tablets 0e

Packaging label for Memantine HCl Tablets, 5 mg and 10 mg strengths, oral tablet dosage form. The label shows a titration pack from Actavis Pharma, Inc. with detailed supply information for memantine hydrochloride tablets. It includes prescription-only designation, NDC number 0591-3900-87, and the titration schedule on the front panel with color-coded strength indicators.*

FDA Label Image

Memantine Hydrochloride Tablets 0f

Package label for Memantine HCl Tablets showing titration dosing instructions for a package containing memantine hydrochloride oral tablets. The label includes a 4-week titration pack layout with tablets arranged in blister form across weeks 1 to 4, including 5 mg and 10 mg strengths, and detailed dosing instructions for each week. The labeler is Actavis Pharma, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.